Ken Griffin
CBIO

Ken Griffin’s Crescent Biopharma CBIO Stock Holding History

Ken Griffin’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-208
Closed -$4.37K – 13459
2025
Q1 		$4.37K Buy
208
+194
+1,386% +$5.19K ﹤0.01% 13896
2024
Q4 		$349 Buy
+14
New +$382 ﹤0.01% 14341
2024
Q3 		– Sell
-178
Closed -$5.01K – 14583
2024
Q2 		$5.01K Buy
178
+9
+5% +$936 ﹤0.01% 13436
2024
Q1 		$50.7K Buy
169
+62
+58% +$18.5K ﹤0.01% 12162
2023
Q4 		$25.3K Buy
+107
New +$16.6K ﹤0.01% 12419
2023
Q3 		– Sell
-123
Closed -$21.4K – 14594
2023
Q2 		$21.4K Sell
123
-67
-35% -$11.2K ﹤0.01% 12677
2023
Q1 		$23.9K Buy
190
+184
+3,067% +$41.4K ﹤0.01% 12922
2022
Q4 		$1.82K Buy
+6
New +$884 ﹤0.01% 14412
2022
Q1 		– Sell
-315
Closed -$45K – 13963
2021
Q4 		$45K Sell
315
-104
-25% -$18.9K ﹤0.01% 13305
2021
Q3 		$92K Sell
419
-151
-26% -$32K ﹤0.01% 12959
2021
Q2 		$132K Buy
570
+129
+29% +$32.8K ﹤0.01% 12647
2021
Q1 		$133K Buy
441
+64
+17% +$22.9K ﹤0.01% 12182
2020
Q4 		$142K Buy
377
+276
+273% +$96.7K ﹤0.01% 9985
2020
Q3 		$31K Buy
+101
New +$38.6K ﹤0.01% 9749
2018
Q2 		– Sell
-140
Closed -$227K – 8989
2018
Q1 		$227K Buy
+140
New +$291K ﹤0.01% 7156

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Ken Griffin's CBIO Position: Q4 2025 in Review

Ken Griffin sold out of Crescent Biopharma (CBIO) in Q4 2025, closing a stake of 25,593 shares — an estimated $304K sold.

Ken Griffin first reported a position in CBIO in Q2 2017 and held it in 26 quarters. The position peaked at $23.4M in Q2 2018. 58 funds tracked by Wall St. Rank hold CBIO as of Q4 2025.

  • Ken Griffin reported no remaining Crescent Biopharma position as of Q4 2025 after selling out during the quarter.
  • Ken Griffin sold 25,593 Crescent Biopharma shares in Q4 2025, an estimated $304K.
  • Ken Griffin first reported a position in Crescent Biopharma in Q2 2017 and held it in 26 quarters.
  • Ken Griffin's Crescent Biopharma position peaked at $23.4M in Q2 2018.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2025.

Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.